Clinical significance of zoledronic acid in combination with calcium tablets and calcitriol for hip biomechanics and bone mineral density after total hip replacement: a prospective randomized controlled trial

Author:

徐 贞东1,杜 庄1,里 清1,王 辛1,王 紫1,邵 华1,胡 宇通2,刘 莫真3

Affiliation:

1. Dalian Municipal Central Hospital

2. The Second Affiliated Hospital of Soochow University

3. 3、The First Affiliated Hospital of Dalian Medical University

Abstract

Abstract

Purpose: To investigate the effects of zoledronic acid (ZA) combined with calcium tablets and calcitriol on bone mineral density (BMD), hip function after total hip arthroplasty (THA). Methods: 50 elderly patients with THA from January 2022 to December 2022 were included in this study. The ZA group was given ZA combined with calcium tablets and calcitriol, while the control group was only given calcium tablets and calcitriol. The preoperative and postoperative BMD, bone metabolism-related indexes, Harris score, incidence of prosthesis loosening and hip biomechanics between the two groups were compared. Results: There were no significant differences in age, sex, Body Mass Index. Postoperative systemic BMD and periprosthetic BMDin ZA group were higher than those in the control group. The BMD in Gruen zones 1, 6 and 7 at postoperative 6 months, Gruen zones 1, 2, 4, 6 and 7 at postoperative 1 year was significantly higher than that in the control group. Postoperative 1 year, the 25-hydroxyvitamin D, procollagen 1 intact N-terminal and Harris score in ZA group were higher than those in control group, the β-type Ⅰ collagen carboxy-terminal peptide was lower. Acetabular height and acetabular deviation in ZA group were significantly better than those in control group at postoperative 1 year. Only 2 cases of prosthesis loosening in control group. Conclusion: ZA can effectively restore the loss of BMD, maintain the biomechanical stability of the hip, and reduce the incidence of prosthesis loosening. It is an effective method to prevent osteoporosis after THA. Trial registration: This study has been registered in the Chinese Clinical Registry (registration No.: ChiCTR2200065144, date: January 2022)

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3